 Shares of Pliant Therapeutics Inc. PLRX soared about 75 in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibrosis met the primary and secondary endpoints in a Phase 2a clinical trial. Pliant, which is testing four different doses of bexotegrast, said 21 patients ... The post : Pliant Therapeutics shares rally 75 appeared first on ForexTV... 